Abstract
Immunoglobulin A (IgA) nephropathy (IgAN) was first described in 1968 by Berger and Hinglais [1] and is now recognized as a distinct clinicopathologic entity with a higher frequency worldwide than any other primary glomerulopathy [2]. It was initially considered a benign condition, but extended follow-up of patients indicated that 20–50 % of adults would ultimately progress to end-stage renal failure [2, 3]. Likewise, the favorable prognosis initially attributed to children with IgAN must be questioned in the light of studies [4–8].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Berger J, Hinglais N. Les depots intercapillaire d’lgA-IgG. J Urol Nephrol. 1968;74:694–5.
D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64(245):709–27.
Emancipator SN, Gallo GR, Lamm ME. IgA nephropathy: perspectives on pathogenesis and classification. Clin Nephrol. 1985;24(4):161–79.
Yoshikawa N, Ito H, Yoshiara S, Nakahara C, Yoshiya K, Hasegawa O, et al. Clinical course of immunoglobulin A nephropathy in children. J Pediatr. 1987;110(4):555–60.
Yoshikawa N, Iijima K, Maehara K, Yoshiara S, Yoshiya K, Matsuo T, et al. Mesangial changes in IgA nephropathy in children. Kidney Int. 1987;32(4):585–9.
Yoshikawa N, Iijima K, Matsuyama S, Suzuki J, Kameda A, Okada S, et al. Repeat renal biopsy in children with IgA nephropathy. Clin Nephrol. 1990;33(4):160–7.
Wyatt RJ, Kritchevsky SB, Woodford SY, Miller PM, Roy 3rd S, Holland NH, et al. IgA nephropathy: long-term prognosis for pediatric patients. J Pediatr. 1995;127(6):913–9.
Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA. Prognostic indicators in children with IgA nephropathy – report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 1994;8(1):15–20.
White RH. Henoch-Schonlein nephritis. Br Med J. 1971;2(5762):653–4.
White RHR, Yoshikawa N, Feehally J. IgA nephropathy and Henoch-Schönlein nephritis. In: Barratt TM, Avner ED, Harmon WE, editors. Pediatric nephrology. 4th ed. Baltimore: Lippincott Williams & Wilkins; 1999. p. 691–706.
Yoshikawa N, Nakanishi K, Iijima K. Henoch-Schönlein purpura. In: Neilson EG, Couser WG, editors. Immunologic renal diseases. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1127–40.
Rook A. William Heberden’s cases of anaphylactoid purpura. Arch Dis Child. 1958;33(169):271.
Osler W. The visceral lesions of purpura and allied conditions. Br Med J. 1914;1(2775):517–25.
Bunchman TE, Mauer SM, Sibley RK, Vernier RL. Anaphylactoid purpura: characteristics of 16 patients who progressed to renal failure. Pediatr Nephrol. 1988;2(4):393–7.
Levy M, Broyer M, Arsan A, Levy-Bentolila D, Habib R. Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol Necker Hosp. 1976;6:183–228.
Gairdner D. The Schonlein-Henoch syndrome (anaphylactoid purpura). Q J Med. 1948;17(66):95–122.
Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65(7):936–41.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187–92.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
Rodicio JL. Idiopathic IgA nephropathy. Kidney Int. 1984;25(4):717–29.
Sehic AM, Gaber LW, Roy 3rd S, Miller PM, Kritchevsky SB, Wyatt RJ. Increased recognition of IgA nephropathy in African-American children. Pediatr Nephrol. 1997;11(4):435–7.
Clarkson AR, Woodroffe AJ, Aarons I. IgA nephropathy and Henoch-Schönlein purpura. In: Schrier R, Gottschalk C, editors. Diseases of the kidney. Boston: Little, Brown; 1996. p. 1645–70.
Cream JJ, Gumpel JM, Peachey RD. Schonlein-Henoch purpura in the adult. A study of 77 adults with anaphylactoid or Schonlein-Henoch purpura. Q J Med. 1970;39(156):461–84.
Sinniah R, Feng PH, Chen BT. Henoch-Schoenlein syndrome: a clinical and morphological study of renal biopsies. Clin Nephrol. 1978;9(6):219–28.
Fogazzi GB, Pasquali S, Moriggi M, Casanova S, Damilano I, Mihatsch MJ, et al. Long-term outcome of Schonlein-Henoch nephritis in the adult. Clin Nephrol. 1989;31(2):60–6.
Meadow SR, Glasgow EF, White RH, Moncrieff MW, Cameron JS, Ogg CS. Schonlein-Henoch nephritis. Q J Med. 1972;41(163):241–58.
Yoshikawa N, Ito H, Yoshiya K, Nakahara C, Yoshiara S, Hasegawa O, et al. Henoch-Schoenlein nephritis and IgA nephropathy in children: a comparison of clinical course. Clin Nephrol. 1987;27(5):233–7.
Knight JF. The rheumatic poison: a survey of some published investigations of the immunopathogenesis of Henoch-Schonlein purpura. Pediatr Nephrol. 1990;4(5):533–41.
Nielsen HE. Epidemiology of Schonlein-Henoch purpura. Acta Paediatr Scand. 1988;77(1):125–31.
Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schonlein purpura in an unselected childhood population. Eur J Pediatr. 1988;147(2):113–5.
Lewis IC. The Schonlein-Henoch syndrome (anaphylactoid purpura) compared with certain features of nephritis and rheumatism. Arch Dis Child. 1955;30(151):212–6.
Kobayashi O, Wada H, Okawa K, Takeyama I. Schonlein-Henoch’s syndrome in children. Contrib Nephrol. 1975;4:48–71.
Counahan R, Winterborn MH, White RH, Heaton JM, Meadow SR, Bluett NH, et al. Prognosis of Henoch-Schonlein nephritis in children. Br Med J. 1977;2(6078):11–4.
Yoshikawa N, White RH, Cameron AH. Prognostic significance of the glomerular changes in Henoch-Schoenlein nephritis. Clin Nephrol. 1981;16(5):223–9.
Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet. 1992;339(8788):280–2.
Koskimies O, Mir S, Rapola J, Vilska J. Henoch-Schonlein nephritis: long-term prognosis of unselected patients. Arch Dis Child. 1981;56(6):482–4.
Galla JH, Kohaut EC, Alexander R, Mestecky J. Racial difference in the prevalence of IgA-associated nephropathies. Lancet. 1984;2(8401):522.
Levy M. Do genetic factors play a role in Berger’s disease? Pediatr Nephrol. 1987;1(3):447–54.
Bhuyan UN, Tiwari SC, Malaviya AN, Srivastava RN, Dash SC, Malhotra KK. Immunopathology & prognosis in Henoch-Schonlein glomerulonephritis. Indian J Med Res. 1986;83:33–40.
Farley TA, Gillespie S, Rasoulpour M, Tolentino N, Hadler JL, Hurwitz E. Epidemiology of a cluster of Henoch-Schonlein purpura. Am J Dis Child. 1989;143(7):798–803.
Ostergaard JR, Storm K, Lamm LU. Lack of association between HLA and Schoenlein-Henoch Purpura. Tissue Antigens. 1990;35(5):234–5.
Jin DK, Kohsaka T, Kobayashi N. The polymorphism of the immunoglobulin heavy chain switch region gene in IgA nephropathy, Henoch-Schonlein nephritis and idiopathic nephrotic syndrome. Pediatr Nephrol. 1993;7(4):449–51.
Philpott MG. The Schoenlein-Henoch syndrome in childhood with particular reference to the occurrence of nephritis. Arch Dis Child. 1952;27(135):480–1.
Derham RJ, Rogerson MM. The Schonlein-Henoch syndrome with particular reference to renal sequelae. Arch Dis Child. 1956;31(159):364–8.
Koskimies O, Rapola J, Savilahti E, Vilska J. Renal involvement in Schonlein-Henoch purpura. Acta Paediatr Scand. 1974;63(3):357–63.
Ilan Y, Naparstek Y. Schonlein-Henoch syndrome in adults and children. Semin Arthritis Rheum. 1991;21(2):103–9.
Zurowska AM, Wrzolkowa T, Uszycka-Karcz M. Henoch-Schonlein nephritis in children – a clinicopathological study. Int J Pediatr Nephrol. 1985;6(3):183–8.
Habib R, Niaudet P, Levy M. Schönlein-Henoch purpura nephritis and IgA nephropathy. In: Tisher CBB, editor. Renal pathology: with clinical and functional correlations. 2nd ed. Philadelphia: JB Lippincott; 1994. p. 472–523.
Feehally J. Immune mechanisms in glomerular IgA deposition. Nephrol Dial Transplant. 1988;3(4):361–78.
Odum J, Peh CA, Clarkson AR, Bannister KM, Seymour AE, Gillis D, et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant. 1994;9(3):309–12.
Suzuki S, Nakatomi Y, Sato H, Tsukada H, Arakawa M. Haemophilus parainfluenzae antigen and antibody in renal biopsy samples and serum of patients with IgA nephropathy. Lancet. 1994;343(8888):12–6.
Ogura Y, Suzuki S, Shirakawa T, Masuda M, Nakamura H, Iijima K, et al. Haemophilus parainfluenzae antigen and antibody in children with IgA nephropathy and Henoch-Schonlein nephritis. Am J Kidney Dis. 2000;36(1):47–52.
Koyama A, Sharmin S, Sakurai H, Shimizu Y, Hirayama K, Usui J, et al. Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. Kidney Int. 2004;66(1):121–32.
Schmitt R, Lindahl G, Karpman D. Antibody response to IgA-binding streptococcal M proteins in children with IgA nephropathy. Nephrol Dial Transplant. 2010;25(10):3434–6.
Coppo R, Camilla R, Alfarano A, Balegno S, Mancuso D, Peruzzi L, et al. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int. 2009;75(5):536–41.
Ayoub EM, Hoyer J. Anaphylactoid purpura: streptococcal antibody titers and beta1c-globulin levels. J Pediatr. 1969;75(2):193–201.
Meadow SR, Scott DG. Berger disease: Henoch-Schonlein syndrome without the rash. J Pediatr. 1985;106(1):27–32.
Garty BZ, Danon YL, Nitzan M. Schoenlein-Henoch purpura associated with hepatitis A infection. Am J Dis Child. 1985;139(6):547.
Maggiore G, Martini A, Grifeo S, De Giacomo C, Scotta MS. Hepatitis B virus infection and Schonlein-Henoch purpura. Am J Dis Child. 1984;138(7):681–2.
Rasmussen NH. Henoch-Schonlein purpura after yersiniosis. Arch Dis Child. 1982;57(4):322–3.
Roza M, Galbe M, Gonzalez Baschwitz C, Fernandez M, Miguell MA. Henoch-Schoenlein purpura after shigellosis. Clin Nephrol. 1983;20(5):269.
Liew SW, Kessel I. Letter: mycoplasmal pneumonia preceding Henoch-Schonlein purpura. Arch Dis Child. 1974;49(11):912–3.
Alwar AJ. Schonlein-Henoch syndrome: a case report and literature review. East Afr Med J. 1982;59(5):357–60.
Jimenez EL, Dorrington HJ. Vaccination and Henoch-Schoenlein purpura. N Engl J Med. 1968;279(21):1171.
Patel U, Bradley JR, Hamilton DV. Henoch-Schonlein purpura after influenza vaccination. Br Med J (Clin Res Ed). 1988;296(6639):1800.
Burke DM, Jellinek HL. Nearly fatal case of Schoenlein-Henoch syndrome following insect bite. AMA Am J Dis Child. 1954;88(6):772–4.
Rogers PW, Bunn Jr SM, Kurtzman NA, White MG. Schonlein-Henoch syndrome associated with exposure to cold. Arch Intern Med. 1971;128(5):782–6.
Talbot D, Craig R, Falconer S, Tomson D, Milne DD. Henoch-Schonlein purpura secondary to trauma. Arch Dis Child. 1988;63(9):1114–5.
Kimmel PL, Phillips TM, Ferreira-Centeno A, Farkas-Szallasi T, Abraham AA, Garrett CT. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327(10):702–6.
Furukawa T, Hisao O, Furuta S, Shigematsu H. Henoch-Schonlein purpura with nephritis in a patient with Behcet’s disease. Am J Kidney Dis. 1989;13(6):497–500.
Yamabe H, Ozawa K, Fukushi K, Kubota H, Ohsawa H, Akitsu H, et al. IgA nephropathy and Henoch-Schonlein purpura nephritis with anterior uveitis. Nephron. 1988;50(4):368–70.
Cairns SA, Mallick NP, Lawler W, Williams G. Squamous cell carcinoma of bronchus presenting with Henoch-Schonlein purpura. Br Med J. 1978;2(6135):474–5.
Mitsuhashi H, Mitsuhashi M, Tsukada Y, Yano S, Naruse T. Henoch-Schonlein purpura in rheumatoid arthritis. J Rheumatol. 1994;21(6):1138–40.
Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N. Group A streptococcal antigen in the glomeruli of children with Henoch-Schonlein nephritis. Am J Kidney Dis. 2003;41(2):366–70.
Schmitt R, Carlsson F, Morgelin M, Tati R, Lindahl G, Karpman D. Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. Am J Pathol. 2010;176(2):608–18.
Hsu SI, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int. 2000;57(5):1818–35.
Rambausek MH, Waldherr R, Ritz E. Immunogenetic findings in glomerulonephritis. Kidney Int Suppl. 1993;39:S3–8.
Schmidt S, Ritz E. Genetic factors in IgA nephropathy. Ann Med Interne. 1999;150(2):86–90.
Julian BA, Quiggins PA, Thompson JS, Woodford SY, Gleason K, Wyatt RJ. Familial IgA nephropathy. Evidence of an inherited mechanism of disease. N Engl J Med. 1985;312(4):202–8.
Wyatt RJ, Rivas ML, Julian BA, Quiggins PA, Woodford SY, McMorrow RG, et al. Regionalization in hereditary IgA nephropathy. Am J Hum Genet. 1987;41(1):36–50.
Scolari F, Amoroso A, Savoldi S, Mazzola G, Prati E, Valzorio B, et al. Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis. 1999;33(5):857–65.
Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000;26(3):354–7.
Bisceglia L, Cerullo G, Forabosco P, Torres DD, Scolari F, Di Perna M, et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet. 2006;79(6):1130–4.
Paterson AD, Liu XQ, Wang K, Magistroni R, Song X, Kappel J, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007;18(8):2408–15.
Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. 2010;21(10):1791–7.
Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43(4):321–7.
Yu XQ, Li M, Zhang H, Low HQ, Wei X, Wang JQ, et al. A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet. 2012;44(2):178–82.
Schena FP, Cerullo G, Rossini M, Lanzilotta SG, D’Altri C, Manno C. Increased risk of end-stage renal disease in familial IgA nephropathy. J Am Soc Nephrol. 2002;13(2):453–60.
Shimomura M, Yoshikawa N, Iijima K, Nakamura H, Miyazaki M, Sakai H. Polymorphism of immunoglobulin heavy chain switch region gene in children with severe IgA nephropathy. Clin Nephrol. 1995;43(4):211–5.
Yano N, Asakura K, Endoh M, Abe Y, Nomoto Y, Sakai H, et al. Polymorphism in the Ialpha1 germ-line transcript regulatory region and IgA productivity in patients with IgA nephropathy. J Immunol. 1998;160(10):4936–42.
Tanaka R, Iijima K, Murakami R, Koide M, Nakamura H, Yoshikawa N. ACE gene polymorphism in childhood IgA nephropathy: association with clinicopathologic findings. Am J Kidney Dis. 1998;31(5):774–9.
Maruyama K, Yoshida M, Nishio H, Shirakawa T, Kawamura T, Tanaka R, et al. Polymorphisms of renin-angiotensin system genes in childhood IgA nephropathy. Pediatr Nephrol. 2001;16(4):350–5.
Nakanishi K, Sako M, Yata N, Aoyagi N, Nozu K, Tanaka R, et al. A-20C angiotensinogen gene polymorphism and proteinuria in childhood IgA nephropathy. Pediatr Nephrol. 2004;19(2):144–7.
Qin YH, Zhou TB, Su LN, Lei FY, Huang WF, Zhao YJ. Association between ACE polymorphism and risk of IgA nephropathy: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2011;12(3):215–23.
Zhou TB, Ou C, Qin YH, Luo W. A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and Henoch-Schonlein purpura nephritis risk in Asian children. Clin Exp Rheumatol. 2012;30(2):315–6.
Vuong MT, Lundberg S, Gunnarsson I, Wramner L, Seddighzadeh M, Hahn-Zoric M, et al. Genetic variation in the transforming growth factor-beta1 gene is associated with susceptibility to IgA nephropathy. Nephrol Dial Transplant. 2009;24(10):3061–7.
Tanaka R, Iijima K, Xu H, Inoue Y, Murakami R, Shirakawa T, et al. Role of platelet-activating factor acetylhydrolase gene mutation in Japanese childhood IgA nephropathy. Am J Kidney Dis. 1999;34(2):289–95.
Li R, Xue C, Li C, Lou T, Tao Y, Li Y, et al. TRAC variants associate with IgA nephropathy. J Am Soc Nephrol. 2009;20(6):1359–67.
Lin J, Huang Y, Zhang X, Chen J, Sheng H. Association of miR-146a rs2910164 with childhood IgA nephropathy. Pediatr Nephrol. 2014;29:1979–86.
Zhu L, Tang W, Li G, Lv J, Ding J, Yu L, et al. Interaction between variants of two glycosyltransferase genes in IgA nephropathy. Kidney Int. 2009;76(2):190–8.
Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, et al. Genetic variant of C1GalT1 contributes to the susceptibility to IgA nephropathy. J Nephrol. 2009;22(1):152–9.
Woo KT, Lau YK, Wong KS, Zhao Y, Chan CM. Parallel genotyping of 10,204 single nucleotide polymorphisms to screen for susceptible genes for IgA nephropathy. Ann Acad Med Singapore. 2009;38(10):894–9.
Beerman I, Novak J, Wyatt RJ, Julian BA, Gharavi AG. The genetics of IgA nephropathy. Nat Clin Pract Nephrol. 2007;3(6):325–38.
Schena FP, D’Altri C, Cerullo G, Manno C, Gesualdo L. ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a meta-analysis. Kidney Int. 2001;60(2):732–40.
Xue C, Nie W, Xu J, Dai B, Mei CL. C509T and T869C polymorphisms of transforming growth factor beta1 and the risk of IgA nephropathy: a meta-analysis. Chin Med J (Engl). 2013;126(23):4562–7.
Takei T, Iida A, Nitta K, Tanaka T, Ohnishi Y, Yamada R, et al. Association between single-nucleotide polymorphisms in selectin genes and immunoglobulin A nephropathy. Am J Hum Genet. 2002;70(3):781–6.
Akiyama F, Tanaka T, Yamada R, Ohnishi Y, Tsunoda T, Maeda S, et al. Single-nucleotide polymorphisms in the class II region of the major histocompatibility complex in Japanese patients with immunoglobulin A nephropathy. J Hum Genet. 2002;47(10):532–8.
Obara W, Iida A, Suzuki Y, Tanaka T, Akiyama F, Maeda S, et al. Association of single-nucleotide polymorphisms in the polymeric immunoglobulin receptor gene with immunoglobulin A nephropathy (IgAN) in Japanese patients. J Hum Genet. 2003;48(6):293–9.
Brogan PA. What’s new in the aetiopathogenesis of vasculitis? Pediatr Nephrol. 2007;22(8):1083–94.
He X, Yu C, Zhao P, Ding Y, Liang X, Zhao Y, et al. The genetics of Henoch-Schonlein purpura: a systematic review and meta-analysis. Rheumatol Int. 2013;33(6):1387–95.
Amoroso A, Danek G, Vatta S, Crovella S, Berrino M, Guarrera S, et al. Polymorphisms in angiotensin-converting enzyme gene and severity of renal disease in Henoch-Schoenlein patients. Italian Group of Renal Immunopathology. Nephrol Dial Transplant. 1998;13(12):3184–8.
Di B, Li X, Song L, Wang Q, Liu S. Association study of ACE and eNOS single nucleotide polymorphisms with Henoch-Schonlein purpura nephritis. Mol Med Rep. 2012;6(5):1171–7.
Amoli MM, Mattey DL, Calvino MC, Garcia-Porrua C, Thomson W, Hajeer AH, et al. Polymorphism at codon 469 of the intercellular adhesion molecule-1 locus is associated with protection against severe gastrointestinal complications in Henoch-Schonlein purpura. J Rheumatol. 2001;28(5):1014–8.
Rueda B, Perez-Armengol C, Lopez-Lopez S, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Association between functional haplotypes of vascular endothelial growth factor and renal complications in Henoch-Schonlein purpura. J Rheumatol. 2006;33(1):69–73.
Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura. J Pediatr. 2003;143(5):658–61.
Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine. 2005;84(1):1–11.
Ozcakar ZB, Yalcinkaya F, Cakar N, Acar B, Kasapcopur O, Uguten D, et al. MEFV mutations modify the clinical presentation of Henoch-Schonlein purpura. J Rheumatol. 2008;35(12):2427–9.
He X, Lu H, Kang S, Luan J, Liu Z, Yin W, et al. MEFV E148Q polymorphism is associated with Henoch-Schonlein purpura in Chinese children. Pediatr Nephrol. 2010;25(10):2077–82.
Sakai H. Current views on pathogenesis and treatment. In: Andreucci VE, editor. International year book of nephrology. Boston: Kluwer; 1989. p. 23–46.
Andresdottir MB, Hoitsma AJ, Assmann KJ, Wetzels JF. Favorable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol. 2001;56(4):279–88.
Yoshikawa N, Iijima K, Ito H. IgA nephropathy in children. Nephron. 1999;83(1):1–12.
Yoshikawa N, Tanaka R, Iijima K. Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol. 2001;16(5):446–57.
Rifai A, Small Jr P, Ayoub EM. Experimental IgA nephropathy. Factors governing the persistence of IgA-antigen complexes in the circulation of mice. Contrib Nephrol. 1984;40:37–44.
Isaacs K, Miller F. Dextran-induced IgA nephropathy. Contrib Nephrol. 1984;40:45–50.
Emancipator SN, Gallo GR, Lamm ME. Experimental IgA nephropathy induced by oral immunization. J Exp Med. 1983;157(2):572–82.
Levinsky RJ, Barratt TM. IgA immune complexes in Henoch-Schonlein purpura. Lancet. 1979;2(8152):1100–3.
Kauffmann RH, Herrmann WA, Meyer CJ, Daha MR, Van Es LA. Circulating IgA-immune complexes in Henoch-Schonlein purpura. A longitudinal study of their relationship to disease activity and vascular deposition of IgA. Am J Med. 1980;69(6):859–66.
Coppo R, Basolo B, Martina G, Rollino C, De Marchi M, Giacchino F, et al. Circulating immune complexes containing IgA. IgG and IgM in patients with primary IgA nephropathy and with Henoch-Schoenlein nephritis. Correlation with clinical and histologic signs of activity. Clin Nephrol. 1982;18(5):230–9.
Baliah T, Kim KH, Anthone S, Anthone R, Montes M, Andres GA. Recurrence of Henoch-Schonlein purpura glomerulonephritis in transplanted kidneys. Transplantation. 1974;18(4):343–6.
Nast CC, Ward HJ, Koyle MA, Cohen AH. Recurrent Henoch-Schonlein purpura following renal transplantation. Am J Kidney Dis. 1987;9(1):39–43.
Hasegawa A, Kawamura T, Ito H, Hasegawa O, Ogawa O, Honda M, et al. Fate of renal grafts with recurrent Henoch-Schonlein purpura nephritis in children. Transplant Proc. 1989;21(1 Pt 2):2130–3.
Davin JC, Dechenne C, Lombet J, Rentier B, Foidart JB, Mahieu PR. Acute experimental glomerulonephritis induced by the glomerular deposition of circulating polymeric IgA-concanavalin A complexes. Virchows Arch A Pathol Anat Histopathol. 1989;415(1):7–20.
Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest. 1980;66(6):1432–6.
Komatsu N, Nagura H, Watanabe K, Nomoto Y, Kobayashi K. Mesangial deposition of J chain-linked polymeric IgA in IgA nephropathy. Nephron. 1983;33(1):61–4.
Bene MC, Faure G, Duheille J. IgA nephropathy: characterization of the polymeric nature of mesangial deposits by in vitro binding of free secretory component. Clin Exp Immunol. 1982;47(3):527–34.
Valentijn RM, Radl J, Haayman JJ, Vermeer BJ, Weening JJ, Kauffmann RH, et al. Macromolecular IgA in the circulation and mesangial deposits in patients with primary IgA nephropathy. Contrib Nephrol. 1984;40:87–92.
Monteiro RC, Halbwachs-Mecarelli L, Berger J, Lesavre P. Characteristics of eluted IgA in primary IgA nephropathy. Contrib Nephrol. 1984;40:107–11.
Tomino Y, Endoh M, Suga T, Miura M, Kaneshige H, Nomoto Y, et al. Prevalence of IgAl deposits in Henoch-Schoenlein purpura (HSP) nephritis. Tokai J Exp Clin Med. 1982;7(4):527–32.
Rajaraman S, Goldblum RM, Cavallo T. IgA-associated glomerulonephritides: a study with monoclonal antibodies. Clin Immunol Immunopathol. 1986;39(3):514–22.
Russell MW, Mestecky J, Julian BA, Galla JH. IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol. 1986;6(1):74–86.
Egido J, Sancho J, Mampaso F, Lopez Trascasa M, Sanchez Crespo M, Blasco R, et al. A possible common pathogenesis of the mesangial IgA glomerulonephritis in patients with Berger’s disease and Schonlein-Henoch syndrome. Proc Eur Dial Transplant Assoc. 1980;17:660–6.
Harper SJ, Pringle JH, Wicks AC, Hattersley J, Layward L, Allen A, et al. Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int. 1994;45(3):836–44.
Harper SJ, Allen AC, Pringle JH, Feehally J. Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol. 1996;49(1):38–42.
de Fijter JW, Eijgenraam JW, Braam CA, Holmgren J, Daha MR, van Es LA, et al. Deficient IgA1 immune response to nasal cholera toxin subunit B in primary IgA nephropathy. Kidney Int. 1996;50(3):952–61.
Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int. 1987;31(3):820–9.
Evans DJ, Williams DG, Peters DK, Sissons JG, Boulton-Jones JM, Ogg CS, et al. Glomerular deposition of properdin in Henoch-Schonlein syndrome and idiopathic focal nephritis. Br Med J. 1973;3(5875):326–8.
Julian BA, Wyatt RJ, McMorrow RG, Galla JH. Serum complement proteins in IgA nephropathy. Clin Nephrol. 1983;20(5):251–8.
Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001;167(5):2861–8.
Abe K, Miyazaki M, Koji T, Furusu A, Ozono Y, Harada T, et al. Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney. Kidney Int. 1998;54(1):120–30.
Kawana S, Shen GH, Kobayashi Y, Nishiyama S. Membrane attack complex of complement in Henoch-Schonlein purpura skin and nephritis. Arch Dermatol Res. 1990;282(3):183–7.
Garcia-Fuentes M, Martin A, Chantler C, Williams DG. Serum complement components in Henoch-Schonlein purpura. Arch Dis Child. 1978;53(5):417–9.
Petersen S, Taaning E, Soderstrom T, Pilgaard B, Tranebjaerg L, Christensen T, et al. Immunoglobulin and complement studies in children with Schonlein-Henoch Syndrome and other vasculitic diseases. Acta Paediatr Scand. 1991;80(11):1037–43.
Kawana S, Nishiyama S. Serum SC5b-9 (terminal complement complex) level, a sensitive indicator of disease activity in patients with Henoch-Schonlein purpura. Dermatology. 1992;184(3):171–6.
Tomino Y, Endoh M, Nomoto Y, Sakai H. Specificity of eluted antibody from renal tissues of patients with IgA nephropathy. Am J Kidney Dis. 1982;1(5):276–80.
Tomino Y, Sakai H, Endoh M, Suga T, Miura M, Kaneshige H, et al. Cross-reactivity of IgA antibodies between renal mesangial areas and nuclei of tonsillar cells in patients with IgA nephropathy. Clin Exp Immunol. 1983;51(3):605–10.
Emancipator SN. Immunoregulatory factors in the pathogenesis of IgA nephropathy. Kidney Int. 1990;38(6):1216–29.
Tomino Y, Sakai H, Endoh M, Miura M, Suga T, Kaneshige H, et al. Cross-reactivity of eluted antibodies from renal tissues of patients with henoch-Schonlein purpura nephritis and IgA nephropathy. Am J Nephrol. 1983;3(6):315–8.
Tomino Y, Endoh M, Miura M, Nomoto Y, Sakai H. Immunopathological similarities between IgA nephropathy and Henoch-Schoenlein purpura (HSP) nephritis. Acta Pathol Jpn. 1983;33(1):113–22.
Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347(10):738–48.
Launay P, Grossetete B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med. 2000;191(11):1999–2009.
Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med. 2001;194(4):417–25.
Haddad E, Moura IC, Arcos-Fajardo M, Macher MA, Baudouin V, Alberti C, et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schonlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol. 2003;14(2):327–37.
Moura IC, Arcos-Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J, et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol. 2004;15(3):622–34.
Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol. 2005;16(9):2667–76.
Rops AL, Figdor CG, van der Schaaf A, Tamboer WP, Bakker MA, Berden JH, et al. The tetraspanin CD37 protects against glomerular IgA deposition and renal pathology. Am J Pathol. 2010;176(5):2188–97.
Allen AC, Feehally J. IgA1 glycosylation and the pathogenesis of IgA nephropathy. Am J Kidney Dis. 2000;35(3):551–6.
Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney Int. 2011;80(1):79–87.
Sediva A, Stejskal J, Bartunkova J, Smetana Jr K, Gabius HJ. Detection of alpha(beta)-N-acetyl-d-galactosamine-binding sites in kidney – relation to Henoch-Schonlein-associated IgA nephropathy. Folia Biol. 1999;45(4):147–50.
Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 1997;52(2):509–16.
Tomana M, Novak J, Julian BA, Matousovic K, Konecny K, Mestecky J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104(1):73–81.
Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol. 1995;100(3):470–4.
Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J. Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int. 2001;60(3):969–73.
Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. 2001;59(3):1077–85.
Smith AC, de Wolff JF, Molyneux K, Feehally J, Barratt J. O-glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol. 2006;17(4):1192–9.
Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol. 1998;9(11):2048–54.
Greer MR, Barratt J, Harper SJ, Allen AC, Feehally J. The nucleotide sequence of the IgA1 hinge region in IgA nephropathy. Nephrol Dial Transplant. 1998;13(8):1980–3.
Allen AC, Topham PS, Harper SJ, Feehally J. Leucocyte beta 1,3 galactosyltransferase activity in IgA nephropathy. Nephrol Dial Transplant. 1997;12(4):701–6.
Amado M, Almeida R, Carneiro F, Levery SB, Holmes EH, Nomoto M, et al. A family of human beta3-galactosyltransferases. Characterization of four members of a UDP-galactose:beta-N-acetyl-glucosamine/beta-nacetyl-galactosamine beta-1,3-galactosyltransferase family. J Biol Chem. 1998;273(21):12770–8.
Zhou D, Berger EG, Hennet T. Molecular cloning of a human UDP-galactose:GlcNAcbeta1,3GalNAc beta1, 3 galactosyltransferase gene encoding an O-linked core3-elongation enzyme. Eur J Biochem. 1999;263(2):571–6.
Allen AC, Bailey EM, Barratt J, Buck KS, Feehally J. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol. 1999;10(8):1763–71.
Sano T, Hiki Y, Kokubo T, Iwase H, Shigematsu H, Kobayashi Y. Enzymatically deglycosylated human IgA1 molecules accumulate and induce inflammatory cell reaction in rat glomeruli. Nephrol Dial Transplant. 2002;17(1):50–6.
Amore A, Cirina P, Conti G, Brusa P, Peruzzi L, Coppo R. Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol. 2001;12(9):1862–71.
Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118(2):629–39.
Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, et al. Aberrant IgA1 Glycosylation Is Inherited in Familial and Sporadic IgA Nephropathy. J Am Soc Nephrol. 2008;19:1008–14.
Harper SJ, Allen AC, Bene MC, Pringle JH, Faure G, Lauder I, et al. Increased dimeric IgA-producing B cells in tonsils in IgA nephropathy determined by in situ hybridization for J chain mRNA. Clin Exp Immunol. 1995;101(3):442–8.
Leung JC, Tang SC, Lam MF, Chan TM, Lai KN. Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy. Kidney Int. 2001;59(1):277–85.
Sinico RA, Fornasieri A, Oreni N, Benuzzi S, D’Amico G. Polymeric IgA rheumatoid factor in idiopathic IgA mesangial nephropathy (Berger’s disease). J Immunol. 1986;137(2):536–41.
Nomoto Y, Suga T, Miura M, Nomoto H, Tomino Y, Sakai H. Characterization of an acidic nuclear protein recognized by autoantibodies in sera from patients with IgA nephropathy. Clin Exp Immunol. 1986;65(3):513–9.
Cederholm B, Wieslander J, Bygren P, Heinegard D. Patients with IgA nephropathy have circulating anti-basement membrane antibodies reacting with structures common to collagen I, II, and IV. Proc Natl Acad Sci U S A. 1986;83(16):6151–5.
O’Donoghue DJ, Feehally J. Autoantibodies in IgA nephropathy. Contrib Nephrol. 1995;111:93–103; discussion 4–6.
Hall RP, Stachura I, Cason J, Whiteside TL, Lawley TJ. IgA-containing circulating immune complexes in patients with igA nephropathy. Am J Med. 1983;74(1):56–63.
Iijima K, Yoshikawa N, Shiozawa S, Matsuyama S, Kobayashi K, Yoshiya K, et al. Immune abnormalities and clinical course in childhood IgA nephropathy. Nephron. 1990;56(3):255–60.
Kameda A, Yoshikawa N, Shiozawa S, Doi K, Nakamura H. Lymphocyte subpopulations and function in childhood IgA nephropathy. Nephron. 1991;59(4):546–51.
Sakai H, Nomoto Y, Arimori S. Decrease of IgA-specific suppressor T cell activity in patients with IgA nephropathy. Clin Exp Immunol. 1979;38(2):243–8.
Sakai H, Endoh M, Tomino Y, Nomoto Y. Increase of IgA specific helper T alpha cells in patients with IgA nephropathy. Clin Exp Immunol. 1982;50(1):77–82.
Roccatello D, Picciotto G, Torchio M, Ropolo R, Ferro M, Franceschini R, et al. Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Lab Invest. 1993;69(6):714–23.
Trygstad CW, Stiehm ER. Elevated serum IgA globulin in anaphylactoid purpura. Pediatrics. 1971;47(6):1023–8.
Simila S, Kouvalainen K, Lanning M. Serum immunoglobulin levels in the course of anaphylactoid purpura in children. Acta Paediatr Scand. 1977;66(5):537–40.
Saulsbury FT. The role of IgA1 rheumatoid factor in the formation of IgA-containing immune complexes in Henoch-Schonlein purpura. J Clin Lab Immunol. 1987;23(3):123–7.
Saulsbury FT. IgA rheumatoid factor in Henoch-Schonlein purpura. J Pediatr. 1986;108(1):71–6.
Saulsbury FT. Heavy and light chain composition of serum IgA and IgA rheumatoid factor in Henoch-Schonlein purpura. Arthritis Rheum. 1992;35(11):1377–80.
Saulsbury FT, Kirkpatrick PR, Bolton WK. IgA antineutrophil cytoplasmic antibody in Henoch-Schonlein purpura. Am J Nephrol. 1991;11(4):295–300.
Ronda N, Esnault VL, Layward L, Sepe V, Allen A, Feehally J, et al. Antineutrophil cytoplasm antibodies (ANCA) of IgA isotype in adult Henoch-Schonlein purpura. Clin Exp Immunol. 1994;95(1):49–55.
Blanco Quiros A, Blanco C, Alvarez J, Solis P, Conde F, Gomez S. Anti-immunoglobulin antibodies in children with Schonlein-Henoch syndrome. Absence of serum anti-IgA antibodies. Eur J Pediatr. 1994;153(2):103–6.
Burden AD, Gibson IW, Rodger RS, Tillman DM. IgA anticardiolipin antibodies associated with Henoch-Schonlein purpura. J Am Acad Dermatol. 1994;31(5 Pt 2):857–60.
Coppo R, Basolo B, Piccoli G, Mazzucco G, Bulzomi MR, Roccatello D, et al. IgA1 and IgA2 immune complexes in primary IgA nephropathy and Henoch-Schonlein nephritis. Clin Exp Immunol. 1984;57(3):583–90.
Waldo FB, Cochran AM. Mixed IgA-IgG aggregates as a model of immune complexes in IgA nephropathy. J Immunol. 1989;142(11):3841–6.
O’Donoghue DJ, Darvill A, Ballardie FW. Mesangial cell autoantigens in immunoglobulin A nephropathy and Henoch-Schonlein purpura. J Clin Invest. 1991;88(5):1522–30.
Jennette JC, Wieslander J, Tuttle R, Falk RJ. Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schonlein purpura: diagnostic value and pathogenic implications. The Glomerular Disease Collaborative Network. Am J Kidney Dis. 1991;18(4):466–71.
Cederholm B, Linne T, Wieslander J, Bygren P, Heinegard D. Fibronectin-immunoglobulin complexes in the early course of IgA and Henoch-Schonlein nephritis. Pediatr Nephrol. 1991;5(2):200–4.
Kuno-Sakai H, Sakai H, Nomoto Y, Takakura I, Kimura M. Increase of IgA-bearing peripheral blood lymphocytes in children with Henoch-Schoenlein purpura. Pediatrics. 1979;64(6):918–22.
Casanueva B, Rodriguez-Valverde V, Merino J, Arias M, Garcia-Fuentes M. Increased IgA-producing cells in the blood of patients with active Henoch-Schonlein purpura. Arthritis Rheum. 1983;26(7):854–60.
Casanueva B, Rodriguez-Valverde V, Luceno A. Circulating IgA producing cells in the differential diagnosis of Henoch-Schonlein purpura. J Rheumatol. 1988;15(8):1229–33.
Casanueva B, Rodriguez-Valverde V, Farinas MC, Vallo A, Rodriguez-Soriano J. Autologous mixed lymphocyte reaction and T-cell suppressor activity in patients with Henoch-Schonlein purpura and IgA nephropathy. Nephron. 1990;54(3):224–8.
Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795–803.
Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119(6):1668–77.
Julian BA, Novak J. IgA nephropathy: an update. Curr Opin Nephrol Hypertens. 2004;13(2):171–9.
Mestecky J, Tomana M, Moldoveanu Z, Julian BA, Suzuki H, Matousovic K, et al. Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res. 2008;31(1):29–37.
Glassock RJ. The pathogenesis of IgA nephropathy. Curr Opin Nephrol Hypertens. 2011;20(2):153–60.
Szeto CC, Li PK. MicroRNAs in IgA nephropathy. Nat Rev Nephrol. 2014;10(5):249–56.
Lorenzen JM, Haller H, Thum T. MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol. 2011;7(5):286–94.
Serino G, Sallustio F, Cox SN, Pesce F, Schena FP. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol. 2012;23(5):814–24.
Fang Y, Yu X, Liu Y, Kriegel AJ, Heng Y, Xu X, et al. miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-alpha activation. Am J Physiol Renal Physiol. 2013;304(10):F1274–82.
Caubet C, Lacroix C, Decramer S, Drube J, Ehrich JH, Mischak H, et al. Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr Nephrol. 2010;25(1):27–35.
Wang G, Kwan BC, Lai FM, Chow KM, Kam-Tao Li P, Szeto CC. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers. 2010;28(2):79–86.
Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis Markers. 2011;30(4):171–9.
Tan K, Chen J, Li W, Chen Y, Sui W, Zhang Y, et al. Genome-wide analysis of microRNAs expression profiling in patients with primary IgA nephropathy. Genome. 2013;56(3):161–9.
Muratsu-Ikeda S, Nangaku M, Ikeda Y, Tanaka T, Wada T, Inagi R. Downregulation of miR-205 modulates cell susceptibility to oxidative and endoplasmic reticulum stresses in renal tubular cells. PLoS One. 2012;7(7):e41462.
Puhr M, Hoefer J, Schafer G, Erb HH, Oh SJ, Klocker H, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181(6):2188–201.
Bao H, Chen H, Zhu X, Zhang M, Yao G, Yu Y, et al. MiR-223 downregulation promotes glomerular endothelial cell activation by upregulating importin alpha4 and alpha5 in IgA nephropathy. Kidney Int. 2014;85(3):624–35.
Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med. 2012;4(121):121ra18.
Chung AC, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol. 2010;21(8):1317–25.
Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):438–47.
Du B, Ma LM, Huang MB, Zhou H, Huang HL, Shao P, et al. High glucose down-regulates miR-29a to increase collagen IV production in HK-2 cells. FEBS Lett. 2010;584(4):811–6.
Liu Y, Taylor NE, Lu L, Usa K, Cowley Jr AW, Ferreri NR, et al. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension. 2010;55(4):974–82.
Wang Q, Wang Y, Minto AW, Wang J, Shi Q, Li X, et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 2008;22(12):4126–35.
Fleissner F, Jazbutyte V, Fiedler J, Gupta SK, Yin X, Xu Q, et al. Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res. 2010;107(1):138–43.
Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006;69(2):213–7.
Stad RK, Bruijn JA, van Gijlswijk-Janssen DJ, van Es LA, Daha MR. An acute model for IgA-mediated glomerular inflammation in rats induced by monoclonal polymeric rat IgA antibodies. Clin Exp Immunol. 1993;92(3):514–21.
Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol. 2000;11(12):2395–403.
Lai KN, Tang SC, Guh JY, Chuang TD, Lam MF, Chan LY, et al. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J Am Soc Nephrol. 2003;14(12):3127–37.
Lai KN, Chan LY, Leung JC. Mechanisms of tubulointerstitial injury in IgA nephropathy. Kidney Int Suppl. 2005;94:S110–5.
Allen AC, Barratt J, Feehally J. Immunoglobulin A nephropathy. In: Neilson EG, Couser WG, editors. Immunologic renal diseases. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 931–47.
Niemir ZI, Stein H, Noronha IL, Kruger C, Andrassy K, Ritz E, et al. PDGF and TGF-beta contribute to the natural course of human IgA glomerulonephritis. Kidney Int. 1995;48(5):1530–41.
Stein-Oakley AN, Maguire JA, Dowling J, Perry G, Thomsom NM. Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis. Kidney Int. 1997;51(1):195–204.
Taniguchi Y, Yorioka N, Masaki T, Asakimori Y, Yamashita K, Yamakido M. Localization of transforming growth factors beta1 and beta2 and epidermal growth factor in IgA nephropathy. Scand J Urol Nephrol. 1999;33(4):243–7.
Tamouza H, Chemouny JM, Raskova Kafkova L, Berthelot L, Flamant M, Demion M, et al. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int. 2012;82(12):1284–96.
Nagata M, Akioka Y, Tsunoda Y, Komatsu Y, Kawaguchi H, Yamaguchi Y, et al. Macrophages in childhood IgA nephropathy. Kidney Int. 1995;48(2):527–35.
Yoshioka K, Takemura T, Murakami K, Okada M, Yagi K, Miyazato H, et al. In situ expression of cytokines in IgA nephritis. Kidney Int. 1993;44(4):825–33.
Iijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 1993;44(5):959–66.
Noguchi K, Yoshikawa N, Ito-Kariya S, Inoue Y, Hayashi Y, Ito H, et al. Activated mesangial cells produce vascular permeability factor in early-stage mesangial proliferative glomerulonephritis. J Am Soc Nephrol. 1998;9(10):1815–25.
Tomino Y, Endoh M, Nomoto Y, Sakai H. Activation of complement by renal tissues from patients with IgA nephropathy. J Clin Pathol. 1981;34(1):35–40.
Kashem A, Endoh M, Nomoto Y, Sakai H, Nakazawa H. Fc alpha R expression on polymorphonuclear leukocyte and superoxide generation in IgA nephropathy. Kidney Int. 1994;45(3):868–75.
Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002;61(4):1475–85.
Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005;16(10):2941–52.
Qiu LQ, Sinniah R, I-Hong Hsu S. Downregulation of Bcl-2 by podocytes is associated with progressive glomerular injury and clinical indices of poor renal prognosis in human IgA nephropathy. J Am Soc Nephrol. 2004;15(1):79–90.
Wang C, Peng H, Tang H, Liu X, Chen Z, Lou T, et al. Serum IgA1 from IgA nephropathy patients induces apoptosis in podocytes through direct and indirect pathways. Clin Invest Med. 2007;30(6):E240–9.
Dillon JJ. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy. Semin Nephrol. 2004;24(3):218–24.
Lai KN, Chan LY, Tang SC, Tsang AW, Li FF, Lam MF, et al. Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int. 2004;66(4):1403–16.
Chan LY, Leung JC, Tsang AW, Tang SC, Lai KN. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int. 2005;67(2):602–12.
Wu Q, Jinde K, Endoh M, Sakai H. Clinical significance of costimulatory molecules CD80/CD86 expression in IgA nephropathy. Kidney Int. 2004;65(3):888–96.
Tang SC, Leung JC, Abe K, Chan KW, Chan LY, Chan TM, et al. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J Clin Invest. 2003;111(4):515–27.
Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int. 1998;53(6):1608–15.
Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol. 1998;9(7):1213–24.
Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol. 1997;8(10):1537–45.
Abbate M, Zoja C, Rottoli D, Corna D, Perico N, Bertani T, et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol. 1999;10(4):804–13.
Tang S, Leung JC, Tsang AW, Lan HY, Chan TM, Lai KN. Transferrin up-regulates chemokine synthesis by human proximal tubular epithelial cells: implication on mechanism of tubuloglomerular communication in glomerulopathic proteinura. Kidney Int. 2002;61(5):1655–65.
Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens. 2004;13(1):31–7.
Galla JH, Spotswood MF, Harrison LA, Mestecky J. Urinary IgA in IgA nephropathy and Henoch-Schoenlein purpura. J Clin Immunol. 1985;5(5):298–306.
Arrizabalaga P, Sole M, Abellana R, de las Cuevas X, Soler J, Pascual J, et al. Tubular and interstitial expression of ICAM-1 as a marker of renal injury in IgA nephropathy. Am J Nephrol. 2003;23(3):121–8.
Arrizabalaga P, Sole M, Quinto IL, Ascaso C. Intercellular adhesion molecule-1 mediated interactions and leucocyte infiltration in IgA nephropathy. Nephrol Dial Transplant. 1997;12(11):2258–62.
Ranieri E, Gesualdo L, Petrarulo F, Schena FP. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 1996;50(6):1990–2001.
Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15(3–4):290–301.
Hirschberg R. Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis. J Am Soc Nephrol. 2005;16(1):9–11.
Yoshikawa N, Ito H, Nakamura H. IgA nephropathy in children from Japan. Clinical and pathological features. Child Nephrol Urol. 1988;9(4):191–9.
Miura M, Tomino Y, Yagame M, Endoh M, Suga T, Nomoto Y, et al. Immunofluorescent studies on alpha 2-plasmin inhibitor (alpha 2-PI) in glomeruli from patients with IgA nephropathy. Clin Exp Immunol. 1985;62(2):380–6.
Yoshikawa N, Ito H, Nakahara C, Yoshiara S, Yoshiya K, Matsuo T, et al. Glomerular electron-dense deposits in childhood IgA nephropathy. Virchows Arch A Pathol Anat Histopathol. 1985;406(1):33–43.
D’Amico G, Minetti L, Ponticelli C, Fellin G, Ferrario F, Barbiano di Belgioioso G, et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med. 1986;59(228):363–78.
Andreoli SP, Yum MN, Bergstein JM. IgA nephropathy in children: significance of glomerular basement membrane deposition of IgA. Am J Nephrol. 1986;6(1):28–33.
Yoshikawa N, Ito H, Nakamura H. Prognostic indicators in childhood IgA nephropathy. Nephron. 1992;60(1):60–7.
Churg J, Bernstein J, Glassock RJ. Renal disease: classification and atlas of glomerular diseases. Tokyo: Igaku-shoin Medical Publishers; 1995. p. 86–8.
Zimmerman SW, Burkholder PM. Immunoglobulin A nephropathy. Arch Intern Med. 1975;135(9):1217–23.
Hara M, Endo Y, Nihei H, Hara S, Fukushima O, Mimura N. IgA nephropathy with subendothelial deposits. Virchows Arch A Pathol Anat Histol. 1980;386(3):249–63.
Suzuki J, Yoshikawa N, Nakamura H. A quantitative analysis of the mesangium in children with IgA nephropathy: sequential study. J Pathol. 1990;161(1):57–64.
Nicholls KM, Fairley KF, Dowling JP, Kincaid-Smith P. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med. 1984;53(210):227–50.
D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004;24(3):179–96.
Wu Q, Tanaka H, Hirukawa T, Endoh M, Fukagawa M. Characterization and quantification of proliferating cell patterns in endocapillary proliferation. Nephrol Dial Transplant. 2012;27(8):3234–41.
Ikezumi Y, Suzuki T, Karasawa T, Hasegawa H, Yamada T, Imai N, et al. Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology. 2011;58(2):198–210.
Yoshikawa N, Yoshiara S, Yoshiya K, Matsuo T, Okada S. Lysis of the glomerular basement membrane in children with IgA nephropathy and Henoch-Shonlein nephritis. J Pathol. 1986;150(2):119–26.
Droz D. Natural history of primary glomerulonephritis with mesangial deposits of IgA. Contrib Nephrol. 1976;2:150–6.
Ibels LS, Gyory AZ. IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature. Medicine. 1994;73(2):79–102.
Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39(3):493–502.
Shima Y, Nakanishi K, Kamei K, Togawa H, Nozu K, Tanaka R, et al. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant. 2011;26(1):163–9.
Ikezumi Y, Suzuki T, Imai N, Ueno M, Narita I, Kawachi H, et al. Histological differences in new-onset IgA nephropathy between children and adults. Nephrol Dial Transplant. 2006;21(12):3466–74.
Haas M, Rahman MH, Cohn RA, Fathallah-Shaykh S, Ansari A, Bartosh SM. IgA Nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant. 2008;23:2537–45.
Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–45.
Park KS, Han SH, Kie JH, Nam KH, Lee MJ, Lim BJ, et al. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy. Hum Pathol. 2014;45(2):236–43.
Haas M, Reich HN. Morphologic markers of progressive immunoglobulin A nephropathy. Adv Chronic Kidney Dis. 2012;19(2):107–13.
Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13(4):314–22.
Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis. 1997;29(6):829–42.
Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76(5):546–56.
Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77(10):921–7.
Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney Int. 2014;85(4):779–93.
Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al. Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011;80(3):310–7.
Shi SF, Wang SX, Jiang L, Lv JC, Liu LJ, Chen YQ, et al. Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification. Clin J Am Soc Nephrol. 2011;6(9):2175–84.
Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011;6(12):2806–13.
Edstrom Halling S, Soderberg MP, Berg UB. Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification). Nephrol Dial Transplant. 2012;27(2):715–22.
Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Hashimura Y, et al. Validity of the Oxford classification of IgA nephropathy in children. Pediatr Nephrol. 2012;27(5):783–92.
Zeng CH, Le W, Ni Z, Zhang M, Miao L, Luo P, et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis. 2012;60(5):812–20.
El Karoui K, Hill GS, Karras A, Moulonguet L, Caudwell V, Loupy A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int. 2011;79(6):643–54.
Alamartine E, Sauron C, Laurent B, Sury A, Seffert A, Mariat C. The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011;6(10):2384–8.
Lee H, Yi SH, Seo MS, Hyun JN, Jeon JS, Noh H, et al. Validation of the Oxford classification of IgA nephropathy: a single-center study in Korean adults. Korean J Intern Med. 2012;27(3):293–300.
Le W, Zeng CH, Liu Z, Liu D, Yang Q, Lin RX, et al. Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol. 2012;13:158.
Kang SH, Choi SR, Park HS, Lee JY, Sun IO, Hwang HS, et al. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2012;27(1):252–8.
Roberts IS. Oxford classification of immunoglobulin A nephropathy: an update. Curr Opin Nephrol Hypertens. 2013;22(3):281–6.
Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86:828–36.
Shima Y, Nakanishi K, Hama T, Sato M, Mukaiyama H, Togawa H, et al. Biopsy timing and Oxford classification variables in Childhood/Adolescent IgA nephropathy. Pediatr Nephrol. 2014.
Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Tsuchimoto A, Noguchi H, et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol. 2013;8(12):2082–90.
Niaudet P, Levy M, Broyer M, Habib R. Clinicopathologic correlations in severe forms of Henoch-Schonlein purpura nephritis based on repeat biopsies. Contrib Nephrol. 1984;40:250–4.
Michalk D, Waldherr R, Seelig HP, Weber HP, Scharer K. Idiopathic mesangial IgA-glomerulonephritis in childhood. Description of 19 pediatric cases and review of the literature. Eur J Pediatr. 1980;134(1):13–22.
Linne T, Aperia A, Broberger O, Bergstrand A, Bohman SO, Rekola S. Course of renal function in IgA glomerulonephritis in children and adolescents. Acta Paediatr Scand. 1982;71(5):735–43.
Levy M, Gonzalez-Burchard G, Broyer M, Dommergues JP, Foulard M, Sorez JP, et al. Berger’s disease in children. Natural history and outcome. Medicine. 1985;64(3):157–80.
A multicenter study of IgA nephropathy in children. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int. 1982;22(6):643–52.
Ueda Y, Sakai O, Yamagata M, Kitajima T, Kawamura K. IgA glomerulonephritis in Japan. Contrib Nephrol. 1975;4:37–47.
Nakamoto Y, Asano Y, Dohi K, Fujioka M, Iida H, Kida H, et al. Primary IgA glomerulonephritis and Schonlein-Henoch purpura nephritis: clinicopathological and immunohistological characteristics. Q J Med. 1978;47(188):495–516.
Silva FG, Hogg RJ. IgA nephropathy. In: Tisher CC, Brenner BM, editors. Renal pathology: with clinical and functional correlations. Philadelphia: Lippincott; 1989. p. 434–93.
Abuelo JG, Esparza AR, Matarese RA, Endreny RG, Carvalho JS, Allegra SR. Crescentic IgA nephropathy. Medicine. 1984;63(6):396–406.
Hastings MC, Moldoveanu Z, Suzuki H, Berthoux F, Julian BA, Sanders JT, et al. Biomarkers in IgA nephropathy: relationship to pathogenetic hits. Expert Opin Med Diagn. 2013;7(6):615–27.
Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71(11):1148–54.
Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–14.
Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23(9):1579–87.
Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One. 2014;9(5):e98081.
Zwirner J, Burg M, Schulze M, Brunkhorst R, Gotze O, Koch KM, et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int. 1997;51(4):1257–64.
Camilla R, Suzuki H, Dapra V, Loiacono E, Peruzzi L, Amore A, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(8):1903–11.
Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol. 2012;7(5):727–34.
Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153–60.
Cheng GY, Liu DW, Zhang N, Tang L, Zhao ZZ, Liu ZS. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up. Clin Nephrol. 2013;80(1):40–6.
Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, van Kooten C, Wramner L, et al. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int. 2010;78(12):1281–7.
Tomino Y, Suzuki S, Imai H, Saito T, Kawamura T, Yorioka N, et al. Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. J Clin Lab Anal. 2000;14(5):220–3.
Nakayama K, Ohsawa I, Maeda-Ohtani A, Murakoshi M, Horikoshi S, Tomino Y. Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading. J Clin Lab Anal. 2008;22(2):114–8.
Komatsu H, Fujimoto S, Hara S, Sato Y, Yamada K, Eto T. Relationship between serum IgA/C3 ratio and progression of IgA nephropathy. Intern Med. 2004;43(11):1023–8.
Ishiguro C, Yaguchi Y, Funabiki K, Horikoshi S, Shirato I, Tomino Y. Serum IgA/C3 ratio may predict diagnosis and prognostic grading in patients with IgA nephropathy. Nephron. 2002;91(4):755–8.
Maeda A, Gohda T, Funabiki K, Horikoshi S, Shirato I, Tomino Y. Significance of serum IgA levels and serum IgA/C3 ratio in diagnostic analysis of patients with IgA nephropathy. J Clin Lab Anal. 2003;17(3):73–6.
Shen P, He L, Jiang Y, Wang C, Chen M. Useful indicators for performing renal biopsy in adult patients with isolated microscopic haematuria. Int J Clin Pract. 2007;61(5):789–94.
Zhang J, Wang C, Tang Y, Peng H, Ye ZC, Li CC, et al. Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy. Nephrology (Carlton). 2013;18(2):125–31.
Stangou M, Alexopoulos E, Papagianni A, Pantzaki A, Bantis C, Dovas S, et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy. Nephrology (Carlton). 2009;14(6):613–20.
Torres DD, Rossini M, Manno C, Mattace-Raso F, D’Altri C, Ranieri E, et al. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 2008;73(3):327–33.
Asao R, Asanuma K, Kodama F, Akiba-Takagi M, Nagai-Hosoe Y, Seki T, et al. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol. 2012;7(9):1385–93.
Peters HP, van den Brand JA, Wetzels JF. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy. Neth J Med. 2009;67(2):54–61.
Liu LL, Jiang Y, Wang LN, Liu N. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin Exp Immunol. 2012;169(2):148–55.
Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005;67(6):2313–20.
Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis. 2007;28(23):4469–83.
Julian BA, Wittke S, Haubitz M, Zurbig P, Schiffer E, McGuire BM, et al. Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases. World J Urol. 2007;25(5):467–76.
Rocchetti MT, Centra M, Papale M, Bortone G, Palermo C, Centonze D, et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics. 2008;8(1):206–16.
Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis? Kidney Int. 2001;59(3):823–34.
Montoliu J, Lens XM, Torras A, Revert L. Henoch-Schonlein purpura and IgA nephropathy in father and son. Nephron. 1990;54(1):77–9.
Araque A, Sanchez R, Alamo C, Torres N, Praga M. Evolution of immunoglobulin A nephropathy into Henoch-Schonlein purpura in an adult patient. Am J Kidney Dis. 1995;25(2):340–2.
Silverstein DM, Greifer I, Folkert V, Bennett B, Corey HE, Spitzer A. Sequential occurrence of IgA nephropathy and Henoch-Schonlein purpura: support for common pathogenesis. Pediatr Nephrol. 1994;8(6):752–3.
Weiss JH, Bhathena DB, Curtis JJ, Lucas BA, Luke RG. A possible relationship between Henoch-Schonlein syndrome and IgA nephropathy (Berger’s disease). An illustrative case. Nephron. 1978;22(4–6):582–91.
Pouria S, Feehally J. Glomerular IgA deposition in liver disease. Nephrol Dial Transplant. 1999;14(10):2279–82.
Kalsi J, Delacroix DL, Hodgson HJ. IgA in alcoholic cirrhosis. Clin Exp Immunol. 1983;52(3):499–504.
Sancho J, Egido J, Sanchez-Crespo M, Blasco R. Detection of monomeric and polymeric IgA containing immune complexes in serum and kidney from patients with alcoholic liver disease. Clin Exp Immunol. 1982;47(2):327–35.
Habib R, Girardin E, Gagnadoux MF, Hinglais N, Levy M, Broyer M. Immunopathological findings in idiopathic nephrosis: clinical significance of glomerular “immune deposits”. Pediatr Nephrol. 1988;2(4):402–8.
D’Amico G, Imbasciati E, Barbiano Di Belgioioso G, Bertoli S, Fogazzi G, Ferrario F, et al. Idiopathic IgA mesangial nephropathy. Clinical and histological study of 374 patients. Medicine. 1985;64(1):49–60.
Droz D, Kramar A, Nawar T, Noel LH. Primary IgA nephropathy: prognostic factors. Contrib Nephrol. 1984;40:202–7.
D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36(2):227–37.
Glassock RJ, Adler SG, Ward HJ, Cohen AH. Primary glomerular diseases. In: Brenner BM, Rector FCJ, editors. The kidney. 4th ed. Philadelphia: Saunders; 1991. p. 1182–279.
Hood SA, Velosa JA, Holley KE, Donadio Jr JV. IgA-IgG nephropathy: predictive indices of progressive disease. Clin Nephrol. 1981;16(2):55–62.
Kobayashi Y, Tateno S, Hiki Y, Shigematsu H. IgA nephropathy: prognostic significance of proteinuria and histological alterations. Nephron. 1983;34(3):146–53.
Katz A, Walker JF, Landy PJ. IgA nephritis with nephrotic range proteinuria. Clin Nephrol. 1983;20(2):67–71.
Chida Y, Tomura S, Takeuchi J. Renal survival rate of IgA nephropathy. Nephron. 1985;40(2):189–94.
Neelakantappa K, Gallo GR, Baldwin DS. Proteinuria in IgA nephropathy. Kidney Int. 1988;33(3):716–21.
Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38(4):728–35.
Hattori S, Karashima S, Furuse A, Terashima T, Hiramatsu M, Murakami M, et al. Clinicopathological correlation of IgA nephropathy in children. Am J Nephrol. 1985;5(3):182–9.
Hogg RJ. Prognostic indicators and treatment of childhood IgA nephropathy. Contrib Nephrol. 1995;111:194–9; discussion 9–200.
Tsuboi N, Kawamura T, Koike K, Okonogi H, Hirano K, Hamaguchi A, et al. Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy. Clin J Am Soc Nephrol. 2010;5(1):39–44.
Espinosa M, Ortega R, Gomez-Carrasco JM, Lopez-Rubio F, Lopez-Andreu M, Lopez-Oliva MO, et al. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant. 2009;24(3):886–91.
Espinosa M, Ortega R, Sanchez M, Segarra A, Salcedo MT, Gonzalez F, et al. Association of c4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2014;9(5):897–904.
Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, et al. Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol. 2008;23:905–12.
Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Sako M, et al. Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol. 2013;28(1):71–6.
Wyatt RJ, Hogg RJ. Evidence-based assessment of treatment options for children with IgA nephropathies. Pediatr Nephrol. 2001;16(2):156–67.
Schlondorff D, Dendorfer U, Brumberger V, Keuneke C. Limitations of therapeutic approaches to glomerular diseases. Kidney Int Suppl. 1995;50:S19–25.
Donadio Jr JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med. 1994;331(18):1194–9.
Donadio Jr JV, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol. 1999;10(8):1772–7.
Donadio Jr JV, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol. 2001;12(4):791–9.
Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol. 1997;8(11):1739–44.
Hogg RJ, Lee J, Nardelli N, Julian BA, Cattran D, Waldo B, et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol. 2006;1(3):467–74.
Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol. 2006;1(6):1167–72.
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol. 1999;10(1):101–9.
Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006;69(11):1934–8.
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939–45.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857–63.
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359–64.
Maschio G, Cagnoli L, Claroni F, Fusaroli M, Rugiu C, Sanna G, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant. 1994;9(3):265–9.
Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol. 1998;9(12):2308–17.
Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol. 2003;14(6):1578–83.
Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, et al. Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2009;24(4):845–9.
Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract. 2009;63(6):880–8.
Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18(6):1880–8.
Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis. 2001;38(1):18–25.
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361(9352):117–24.
Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47(5):751–60.
Bhattacharjee R, Filler G. Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol. 2002;17(4):302–4.
Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol. 2005;64(1):35–40.
Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883–7.
Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157–63.
Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002;13(1):142–8.
Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1(3):511–7.
Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65(5):1842–9.
Frisch G, Lin J, Rosenstock J, Markowitz G, D’Agati V, Radhakrishnan J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20(10):2139–45.
Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68(2):802–12.
Samuels JA, Strippoli GF, Craig JC, Schena FP, Molony DA. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton). 2004;9(4):177–85.
Kamei K, Nakanishi K, Ito S, Saito M, Sako M, Ishikura K, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1301–7.
Yoshikawa N, Nakanishi K, Ishikura K, Hataya H, Iijima K, Honda M. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2008;23:757–63.
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, et al. A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Japanese Pediatric IgA Nephropathy Treatment Study Group. Nippon Jinzo Gakkai Shi. 1997;39(5):503–6.
Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int. 2006;69(11):1939–44.
Locatelli F, Vecchio LD, Pozzi C. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors. Nat Clin Pract Nephrol. 2006;2(1):24–31.
Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546–53.
Hogg RJ. IgA nephropathy: what’s new? Pediatr Nephrol. 2007;22(11):1809–14.
Allen DM, Diamond LK, Howell DA. Anaphylactoid purpura in children (Schonlein-Henoch syndrome): review with a follow-up of the renal complications. AMA J Dis Child. 1960;99:833–54.
Jones NF, Creamer B, Gimlette TM. Hypoproteinaemia in anaphylactoid purpura. Br Med J. 1966;2(5523):1166–8.
Reif S, Jain A, Santiago J, Rossi T. Protein losing enteropathy as a manifestation of Henoch-Schonlein purpura. Acta Paediatr Scand. 1991;80(4):482–5.
Kaku Y, Nohara K, Honda S. Renal involvement in Henoch-Schonlein purpura: a multivariate analysis of prognostic factors. Kidney Int. 1998;53(6):1755–9.
Sano H, Izumida M, Shimizu H, Ogawa Y. Risk factors of renal involvement and significant proteinuria in Henoch-Schonlein purpura. Eur J Pediatr. 2002;161(4):196–201.
Rigante D, Candelli M, Federico G, Bartolozzi F, Porri MG, Stabile A. Predictive factors of renal involvement or relapsing disease in children with Henoch-Schonlein purpura. Rheumatol Int. 2005;25(1):45–8.
Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schonlein purpura. Scand J Rheumatol. 2006;35(1):56–60.
Bogdanovic R. Henoch-Schonlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr. 2009;98(12):1882–9.
Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Arch Dis Child. 2010;95(11):877–82.
Saulsbury FT. Corticosteroid therapy does not prevent nephritis in Henoch-Schonlein purpura. Pediatr Nephrol. 1993;7(1):69–71.
Mollica F, Li Volti S, Garozzo R, Russo G. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. Eur J Pediatr. 1992;151(2):140–4.
Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149(2):241–7.
Dudley J, Smith G, Llewelyn-Edwards A, Bayliss K, Pike K, Tizard J. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP). Arch Dis Child. 2013;98(10):756–63.
Rosenblum ND, Winter HS. Steroid effects on the course of abdominal pain in children with Henoch-Schonlein purpura. Pediatrics. 1987;79(6):1018–21.
Utani A, Ohta M, Shinya A, Ohno S, Takakuwa H, Yamamoto T, et al. Successful treatment of adult Henoch-Schonlein purpura with factor XIII concentrate. J Am Acad Dermatol. 1991;24(3):438–42.
White RH, Cameron JS, Trounce JR. Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome. Br Med J. 1966;2(5518):853–60.
Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Kim PK, et al. Can azathioprine and steroids alter the progression of severe Henoch-Schonlein nephritis in children? Pediatr Nephrol. 2005;20(8):1087–92.
Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatr Nephrol. 1998;12(3):238–43.
Kawasaki Y, Suyama K, Hashimoto K, Hosoya M. Methylprednisolone pulse plus mizoribine in children with Henoch-Schoenlein purpura nephritis. Clin Rheumatol. 2011;30(4):529–35.
Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant. 2004;19(4):858–64.
Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporin A for the treatment of severe Henoch-Schonlein glomerulonephritis. Pediatr Nephrol. 2003;18(11):1138–42.
Shin JI, Park JM, Shin YH, Kim JH, Kim PK, Lee JS, et al. Cyclosporin A therapy for severe Henoch-Schonlein nephritis with nephrotic syndrome. Pediatr Nephrol. 2005;20(8):1093–7.
Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al. Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial. Pediatr Nephrol. 2011;26(12):2159–66.
Park JM, Won SC, Shin JI, Yim H, Pai KS. Cyclosporin A therapy for Henoch-Schonlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol. 2011;26(3):411–7.
Kauffmann RH, Houwert DA. Plasmapheresis in rapidly progressive Henoch-Schoenlein glomerulonephritis and the effect on circulating IgA immune complexes. Clin Nephrol. 1981;16(3):155–60.
Camerone G, Garelli S, Valbonesi M, Mosconi L. Plasma exchange treatment in a patient with severe Schoenlein-Henoch purpura. Minerva Med. 1982;73(18):1185–7.
Coppo R, Basolo B, Roccatello D, Giachino O, Lajolo D, Martina G, et al. Plasma exchange in progressive primary IgA nephropathy. Int J Artif Organs. 1985;8 Suppl 2:55–8.
Hattori M, Ito K, Konomoto T, Kawaguchi H, Yoshioka T, Khono M. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schonlein purpura nephritis in children. Am J Kidney Dis. 1999;33(3):427–33.
Ninchoji T, Kaito H, Nozu K, Hashimura Y, Kanda K, Kamioka I, et al. Treatment strategies for Henoch-Schonlein purpura nephritis by histological and clinical severity. Pediatr Nephrol. 2011;26(4):563–9.
Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP). Cochrane Database Syst Rev. 2009;3:CD005128.
Chartapisak W, Opastiraku S, Willis NS, Craig JC, Hodson EM. Prevention and treatment of renal disease in Henoch-Schonlein purpura: a systematic review. Arch Dis Child. 2009;94(2):132–7.
Davin JC, Coppo R. Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schonlein purpura nephritis. Pediatr Nephrol. 2013;28(10):1897–903.
Davin JC, Coppo R. Henoch-Schonlein purpura nephritis in children. Nat Rev Nephrol. 2014;10(10):563–73.
Farine M, Poucell S, Geary DL, Baumal R. Prognostic significance of urinary findings and renal biopsies in children with Henoch-Schonlein nephritis. Clin Pediatr (Phila). 1986;25(5):257–9.
Schärer K, Krmar R, Querfeld U, Ruder H, Waldherr R, Schaefer F. Clinical outcome of Schonlein-Henoch purpura nephritis in children. Pediatr Nephrol. 1999;13(9):816–23.
Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, et al. Predictors of outcome in Henoch-Schonlein nephritis in children and adults. Am J Kidney Dis. 2006;47(6):993–1003.
Butani L, Morgenstern BZ. Long-term outcome in children after Henoch-Schonlein purpura nephritis. Clin Pediatr (Phila). 2007;46(6):505–11.
Edstrom Halling S, Soderberg MP, Berg UB. Predictors of outcome in Henoch-Schonlein nephritis. Pediatr Nephrol. 2010;25(6):1101–8.
Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet. 2002;360(9334):666–70.
Halling SF, Soderberg MP, Berg UB. Henoch Schonlein nephritis: clinical findings related to renal function and morphology. Pediatr Nephrol. 2005;20(1):46–51.
Shin JI, Park JM, Kim JH, Lee JS, Jeong HJ. Factors affecting histological regression of crescentic Henoch-Schonlein nephritis in children. Pediatr Nephrol. 2006;21(1):54–9.
Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int. 1983;23(4):647–55.
Meulders Q, Pirson Y, Cosyns JP, Squifflet JP, van Ypersele de Strihou C. Course of Henoch-Schonlein nephritis after renal transplantation. Report on ten patients and review of the literature. Transplantation. 1994;58(11):1179–86.
White RHR, Yoshikawa N. Henoch-Schönlein nephritis. In: Holliday MA, Barratt TM, Avner ED, editors. Pediatric nephrology. Baltimore: Williams & Wilkins; 1993. p. 729–38.
White RHR. Henoch-Schönlein purpura. In: Churg A, Churg J, editors. Systemic vasculitides. New York: Igaku-Shoin; 1991:203–217.
KDIGO guidelines on glomerulonephritis Chapter 11: Henoch–Schönlein purpura nephritis. Kidney Int Suppl. 2012;2:218–220; doi:10.1038/kisup.2012.24.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Nakanishi, K., Yoshikawa, N. (2016). Immunoglobulin A Nephropathies in Children (Includes HSP). In: Avner, E., Harmon, W., Niaudet, P., Yoshikawa, N., Emma, F., Goldstein, S. (eds) Pediatric Nephrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43596-0_28
Download citation
DOI: https://doi.org/10.1007/978-3-662-43596-0_28
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43595-3
Online ISBN: 978-3-662-43596-0
eBook Packages: MedicineReference Module Medicine